Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: etanercept

Case Report: Pulmonary Sarcoid-Like Reaction in Patient Treated with Etanercept

Luis Lora Garcia, MD, Sneha Centala, MD, MS, Gitanjali Lobo, MD, Shahla Mallick, MD, & Diana Girnita, MD, PhD  |  April 15, 2022

Sarcoidosis is a multisystem disease characterized by noncaseating granulomas in affected tissues, mostly involving the lungs and lymph nodes.1,2 The etiology of sarcoidosis remains unknown but is thought to be due to an inflammatory response to an antigen exposure in genetically predisposed individuals.1 Tumor necrosis factor-α (TNF‑α), a pro-inflammatory cytokine, plays an essential role in…

Filed under:ConditionsOther Rheumatic Conditions Tagged with:case reportetanerceptFellowspulmonary sarcoidosisSarcoidosis

Injection Pen May Reduce Injection Fear Among RA Patients Taking Etanercept Biosimilar

Michele B. Kaufman, PharmD, BCGP  |  May 28, 2021

Fear of injection decreased when patients with RA switched from self-administering a treatment biosimilar to etanercept in a prefilled syringe to an injector pen, according to a small observational study.

Filed under:Biologics/DMARDsDrug Updates Tagged with:Biosimilarsetanerceptinjection pensyringeYLB113-002

Remembering Etanercept & the Advent of the Biologic Era

Robert S. Katz, MD  |  February 10, 2020

As a veteran rheumatologist, I remember the clinical trials of etanercept’s (Enbrel’s) efficacy. And when the drug was first approved in 1998, I participated in those clinical trials and realized the effectiveness was astonishing. It was easy to tell which patients were treated with etanercept vs. those who received placebo, even though both groups were…

Filed under:Biologics/DMARDsSpeak Out Rheum Tagged with:etanerceptSpeak Out Rheumatology

RA Patients May Be Less Likely to Discontinue Etanercept Than Other TNF Inhibitors

Lara C. Pullen, PhD  |  January 8, 2020

In a systematic literature review, researchers found that rheumatoid arthritis patients taking etanercept were less likely to discontinue their treatment than patients using any of five other tumor necrosis factor inhibitors…

Filed under:ConditionsRheumatoid Arthritis Tagged with:etanerceptRheumatoid Arthritis (RA)TNF inhibitors

Etanercept Biosimilar Is Effective, Well-Tolerated for Rheumatoid Arthritis

David Douglas  |  February 16, 2018

NEW YORK (Reuters Health)—The biosimilar LBEC0101 is equivalent to etanercept (Enbrel) in treating patients with rheumatoid arthritis (RA) who respond inadequately to methotrexate, according to researchers from Korea and Japan. As Dr. Yeong-Wook Song tells Reuters Health by email, “LBEC0101 is comparable in efficacy, safety and immunogenicity profile to Enbrel.” The findings, he adds, could…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiosimilarsetanerceptLBEC0101Rheumatoid Arthritis (RA)

Etanercept’s New Autoinjection System; Plus FDA Approves Ixekizumab for Active PsA

Michele B. Kaufman, PharmD, BCGP  |  January 2, 2018

In the U.S., a new formulation and an ergonomic delivery system for single doses of etanercept are now available for RA patients…

Filed under:Biologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:auto-injectoretanerceptixekizumabPsoriatic ArthritisRheumatoid Arthritis (RA)U.S. Food and Drug Administration (FDA)

Rheumatology Drug Updates: Giant Cell Arteritis Relapse Possible if Tocilizumab Discontinued; Plus Updates on Rituximab, Etanercept

Michele B. Kaufman, PharmD, BCGP  |  January 19, 2017

GCA Relapse Possible When Discontinuing Tocilizumab In a Phase 2 randomized, controlled trial, tocilizumab, an anti-IL-6 biologic agent, was shown to induce and maintain remission for up to 52 weeks in patients with giant cell arteritis (GCA).1 During this trial, patients with GCA were randomized in a 2:1 ratio to receive 8 mg/kg bodyweight tocilizumab…

Filed under:Drug UpdatesResearch Rheum Tagged with:ApprovalsdrugetanerceptFDAGiant Cell Arteritisoutcomepatient careQualityrelapseResearchrheumatologyrituximabSafetytrial

FDA Update on Rituximab & Etanercept; Plus New ACP Gout Guideline

Michele B. Kaufman, PharmD, BCGP  |  November 30, 2016

The FDA is considering an application for subcutaneous rituximab and has approved an application for etanercept to treat pediatric patients with plaque psoriasis…

Filed under:Biologics/DMARDsConditionsDrug UpdatesGout and Crystalline ArthritisPediatric Conditions Tagged with:American College of PhysiciansetanerceptFDAFood and Drug AdministrationGoutguidelinePediatricplaque psoriasisrituximab

FDA Approves Etanercept-szzs Biosimilar

Michele B. Kaufman, PharmD, BCGP  |  September 2, 2016

Although it may not be available until 2017, the FDA approved the use of etanercept-szzs for multiple autoimmune diseases…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Biosimilarsetanerceptetanercept-szzsFDAFood and Drug Administration

U.S. FDA Approves Biosimilar to Etanercept

Reuters Staff  |  August 30, 2016

(Reuters)—The U.S. Food and Drug Administration on Tuesday approved Novartis AG’s biosimilar version of Amgen Inc.’s arthritis drug etanercept (Enbrel). The FDA approved the drug, Erelzi, known also as etanercept-szzs, for multiple inflammatory conditions, including rheumatoid arthritis and plaque psoriasis, a skin condition. The agency approved the drug as a biosimilar, meaning there is no…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Biosimilarsetanerceptetanercept-szzsFDAFood and Drug Administration

  • 1
  • 2
  • 3
  • …
  • 31
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences